[Evaluation of the quality of the sentinel lymph node biopsy procedure in patients with breast cancer]
- PMID: 20637527
- DOI: 10.1016/j.remn.2010.05.003
[Evaluation of the quality of the sentinel lymph node biopsy procedure in patients with breast cancer]
Abstract
The Sentinel Lymph Node Biopsy (SLNB) has been demonstrated to be a safe alternative to axillary lymph node dissection in breast cancer staging. The multidisciplinary team must do it with rigor and demonstrate that they have fulfilled some essential criteria.
Objective: To evaluate the quality of the procedure in the Breast Pathology Unit of Hospital Puerta del Mar, using the self-evaluation guidelines of the Spanish Society of Senology and Breast Pathology.
Material and method: These guidelines establish some objective and measurable evaluation criteria related to the aspects that intervene in the SLNB. Each criterion is associated to 4 levels of quality standards. There are 3 essential criteria of mandatory fulfillment to implement SLNB in the clinical practice. They evaluate care experience (6 criteria), operative aspects (18 criteria, 3 essential) and scientific activity (8 indicators). The initial validation phase included 50 patients and the application phase 120 patients (February 2009).
Results: Three essential criteria related to the detection of the sentinel node (98%), accredited sensitivity (90%), and mean number of axillary sentinel nodes (2.1) were fulfilled. The application of self-evaluation guidelines in our Unit obtained a global score of 39 out of 71 points, quality level II being the most prevalent.
Conclusion: During the validation phase, our unit fulfilled the criteria established to implement the procedure. Following that, the use of this guideline accredits the good practice of the SLNB procedure and makes it possible to identify the areas of improvement, in our case, those related to the scientific and training activities.
Copyright © 2010 Elsevier España, S.L. y SEMNIM. All rights reserved.
Similar articles
-
Sentinel lymph node biopsy for breast cancer.Cancer Biother Radiopharm. 2001 Oct;16(5):347-57. doi: 10.1089/108497801753354258. Cancer Biother Radiopharm. 2001. PMID: 11776752 Review.
-
[Axillary recurrences after sentinel lymph node biopsy in initial breast cancer].Rev Esp Med Nucl. 2010 Sep-Oct;29(5):241-5. doi: 10.1016/j.remn.2010.02.007. Epub 2010 May 13. Rev Esp Med Nucl. 2010. PMID: 20466461 Spanish.
-
Factors affecting sentinel lymph node detection failure in breast cancer patients using intradermal injection of the tracer.Rev Esp Med Nucl. 2010 Mar-Apr;29(2):73-7. doi: 10.1016/j.remn.2009.10.001. Epub 2009 Nov 22. Rev Esp Med Nucl. 2010. PMID: 19931946
-
Selective sentinel lymph node mapping and dissection for breast cancer.Cancer Treat Res. 2002;111:65-79. doi: 10.1007/0-306-47822-6_4. Cancer Treat Res. 2002. PMID: 12380175 Review. No abstract available.
-
Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase.Breast Cancer Res Treat. 2006 Sep;99(2):203-8. doi: 10.1007/s10549-006-9192-1. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541308 Clinical Trial.
Cited by
-
The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach.Nucl Med Biol. 2016 Mar;43(3):215-25. doi: 10.1016/j.nucmedbio.2015.11.007. Epub 2015 Dec 3. Nucl Med Biol. 2016. PMID: 26924502 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical